Global Big Pharma Partnering Deal Terms and Agreements Directory 2020: Access Agreements Announced in the Life Sciences Since 2014 - ResearchAndMarkets.com

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Global Big Pharma Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Friday, September 18, 2020
Information
Tags: 
Health, Pharmaceutical, Pharmaceutical industry, Big Pharma
Summary
Key Points: 
  • Global Big Pharma Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals.
  • This report provides details of the latest Big Pharma agreements announced in the life sciences since 2014.
  • The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.
  • Insight into terms included in a Big Pharma partnering agreement, with real world examples
    Available deals are listed by:


The "Global Big Pharma Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.

Global Big Pharma Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Big Pharma agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

One of the key highlights of the report is that over 3,000 online deal records of actual Big Pharma deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Key benefits

  • In-depth understanding of Big Pharma deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Big Pharma agreements with real life case studies
  • Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
  • Identify most active Big Pharma dealmakers since 2014
  • Insight into terms included in a Big Pharma partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Big Pharma dealmaking

2.1. Introduction

2.2. Big Pharma partnering over the years

2.3. Most active Big Pharma dealmakers

2.4. Big Pharma partnering by deal type

2.5. Big Pharma partnering by therapy area

2.6. Big Pharma partnering by technology type

2.7. Deal terms for Big Pharma partnering

2.7.1 Big Pharma partnering headline values

2.7.2 Big Pharma deal upfront payments

2.7.3 Big Pharma deal milestone payments

2.7.4 Big Pharma royalty rates

Chapter 3 - Leading Big Pharma deals

3.1. Introduction

3.2. Top Big Pharma deals by value

Chapter 4 - Most active Big Pharma dealmakers

4.1. Introduction

4.2. Most active Big Pharma dealmakers

4.3. Most active Big Pharma partnering company profiles

Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others

Chapter 5 - Big Pharma contracts dealmaking directory

5.1. Introduction

5.2. Big Pharma contracts dealmaking directory

Chapter 6 - Big Pharma dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 - Big Pharma deals by company A-Z

Appendix 2 - Big Pharma deals by stage of development

Appendix 3 - Big Pharma deals by deal type

Appendix 4 - Big Pharma deals by therapy area

Appendix 5 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/p27sov

Copyright: 
Copyright Business Wire 2020